natgillin/translations-raw huggingface dataset:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
A compound selected from the group consisting of 2,3,4,9-tetrahydro-1 H -carbazoles of the Formula I: wherein R1, R2, R3 and R4 independently represent hydrogen, alkyl, alkoxy, halogen, nitro, cyano, trifluoromethyl, or formyl; 
Spoj, naznačen time, da je odabran iz skupine koja se sastoji od 2,3,4,9-tetrahidro-1H-karbazola formule I: [image] pri čemu, R2, R3 i R4 neovisno predstavljaju vodik, alkil, alkoksi, halogen, nitro, cijano, trifluorometil ili formil;
wherein the terms "alkyl", and "cycloalkyl", if not explicitly stated otherwise, have the following meanings: 
pri čemu izrazi "alkil" i "cikloalkil", ako nije izričito drugačije rečeno, imaju sljedeća značenja:
the term "alkyl" as used herein, alone or in any combination, refers to a saturated aliphatic group including a straight or branched hydrocarbon chain containing 1-7 carbon atoms, wherein the alkyl group can optionally be substituted with one or more substituents, each independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, amino, aminocarbonyl, aryl, arylalkenyl, arylalkyloxy, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxy, cyano, formyl, halogen, haloalkoxy, heterocyclyl, hydroxy, mercapto, and nitro, appended to any carbon atom of the alkyl moiety; 
izraz "alkil" kao što se ovdje koristi, sam ili u bilo kojem sastavu, odnosi se na zasićenu alifatsku skupinu uključujući ravnolančani ili razgranati ugljikovodični lanac koji se sastoji od 1 do 7 ugljikovih atoma, dok alkilna skupina može biti opcijski supstituirana s jednim ili više supstituenata, od kojih je svaki neovisno odabran od sljedećih: alkenil, alkoksi, alkoksikarbonil, alkilkarbonil, alkilkarboniloksi, alkilendioksi, alkilsulfinil, alkilsulfonil, alkiltio, alkinil, amino, aminokarbonil, aril, arilalkenil, arilalkiloksi, ariloksi, ariloksikarbonil, arilsulfinil, arilsulfonil, ariltio, karboksi, cijano, formil, halogen, haloalkoksi, heterociklil, hidroksi, merkapto i nitro, pridodanog na bilo koji ugljikov atom alkilne polovice;
or a pharmaceutically acceptable salt thereof. A compound according to any one of claims 1 to 4, wherein R7 and R8, together with the nitrogen atom to which they are attached, form a dihydro-dibenzo[b, f]azocine, dihydro-indole, dihydroisoquinoline, dihydroquinoline, or dibenzoazepine ring; 
Spoj prema bilo kojem zahtjevu 1 do 4, naznačen time, da R7 i R8, zajedno s dušikovim atomom na koji su priključeni, tvore dihidro-dibenzo[b,f]azocin, dihidro-indol, dihidroizokinolin, dihidrokinolin ili dibenzoazepin prsten; ili njegova farmaceutski prihvatljiva sol.
represents hydrogen or alkyl; 
predstavlja vodik ili alkil;
A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 13, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač.
Use of a compound according to any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention and/or treatment of diseases selected from the group consisting of both chronic and acute allergic diseases or immune disorders comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease, dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, and eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, and basophil-related diseases, such as basophilic leukemia and basophilic leukocytosis. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 12, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju i/ili liječenje bolesti odabranih iz skupine koja sadrži bilo kronične bilo akutne alergijske bolesti ili poremećaje imuniteta koji se sastoje od alergijske astme, rinitisa, kronične opstrukcijske plućne bolesti, dermatitisa, upalne bolesti crijeva, reumatoidnog artritisa, alergijskog nefritisa, konjunktivitisa, atopičnog dermatitisa, bronhijalne astme, alergije na hranu, sistemskog staničnog mastičnog poremećaja, anafilaktičkog šoka, urtikarije, ekcema, svraba, upale, ishemijske-reperfuzijske ozljede, cerebrovaskularnih poremećaja, pleuritisa, ulcerativnog kolitisa, i bolesti povezane s eozinofilom, kao što su Churg-Strauss-ov sindrom i sinusitis, te bolesti povezane s bazofilom, kao što su bazofilna leukemija i bazofilna leukocitoza.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s nepoželjnim upalnim imunosnim odgovorom, te svim bolestima i stanjima uzrokovanim ili povezanim s prekomjernim izlučivanjem TNF-a i IL-1.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of inflammatory conditions and immune or anaphylactic disorders associated with infiltration of leukocytes into inflamed tissue. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
Use according to claim 11, wherein said inflammatory conditions and immune disorders are selected from the group consisting of inflammatory conditions or immune disorders of the lungs, joints, eyes, bowel, skin, and heart. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože i srca.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with excessive unregulated production of cytokines or inflammatory mediators. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kronične opstruktivne plućne bolesti.
Use of a compound or a pharmaceutically acceptable salt or solvate thereof as claimed in any of claims 1 to 3 in the manufacture of a medicament for the treatment of psoriasis. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psorijaze.
A pharmaceutical composition including (i) an active ingredient selected from: a compound of claim 1, a pharmaceutically acceptable salt of claim 2, and a prodrug of claim 3; and (ii) a pharmaceutically acceptable diluent, excipient or carrier. 
Farmaceutska smjesa koja sadrži (i) djelatnu tvar koja se izabire između: spoja prema zahtjevu 1, farmaceutski prihvatljive soli prema zahtjevu 2, i prolijeka prema zahtjevu 3; i (ii) farmaceutski prihvatljivo punilo, pomoćnu tvar ili nosač.
The pharmaceutical composition of claim 4 or 5, comprising a therapeutically effective amount of said active ingredient. 
Farmaceutska smjesa prema zahtjevu 4 ili 5, koja sadrži terapijski učinkovitu količinu spomenute djelatne tvari.
A method for killing or inhibiting the proliferation or growth of a tumor cell, comprising contacting said tumor cell with a compound of claim 1 or a salt form thereof, wherein said tumor cell is exposed to said compound or salt form thereof in vitro, particularly wherein said tumor cell is a malignant cell of an individual. 
Postupak ubijanja ili inhibicije proliferacije ili rasta tumorskih stanica, koji obuhvaća dovođenje u doticaj tumorske stanice sa spojem prema zahtjevu 1 ili njegovim oblikom soli, pri čemu se in vitro ta tumorska stanica izlaže spoju ili njegovoj soli, posebno kada je tumorska stanica maligna stanica pojedinca.
The active ingredient or pharmaceutical composition of claim 12, wherein said disorder or disease is associated with the activity of CDK9. 
Djelatna tvar ili farmaceutska smjesa prema zahtjevu 12, pri čemu je poremećaj ili bolest povezana s aktivnošću CDK9.
A method of synthesizing a pharmaceutically acceptable salt of claim 2, comprising the step of reacting a compound of claim 1 with an acid, particularly wherein the acid is either hydrochloric acid or maleic acid. 
Postupak sinteze farmaceutski prihvatljive soli prema 2, koji obuhvaća korak reakcije spoja prema zahtjevu 1 s kiselinom, posebno kada je kiselina klorovodična ili maleinska kiselina.
A compound of any one of claims 1 to 6 for use in a method of inhibiting the cholesteryl ester transfer protein. 
Spoj prema bilo kojem od zahtjeva 1 do 6 za uporabu u postupku inhibicije proteina prijenosnika kolesteril estera.
A compound of any one of claims 1 to 6 for use in a method for treating, preventing or slowing the progression of Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal. 
Spoj prema bilo kojem od zahtjeva 1 do 6 za uporabu u postupku liječenja, prevencije ili usporavanja napredovanja Alzheimerove bolesti, ateroskleroze, venske tromboze, periferne vaskularne bolesti, dislipidemije, hiperbetalipoproteinemije, hipoalfalipoproteinemije, hiperkolesterolemije, hipertrigliceridemije, obiteljske hiperkolesterolemije, kardiovaskularnih poremećaja, angine, ishemije, srčane ishemije, moždanog udara, infarkta miokarda, reperfuzijske ozljede, angioplastične restenoze, hipertenzije, vaskularnih komplikacija dijabetesa, pretilosti ili endotoksemije kod sisavca.
A compound of any one of claims 1 to 6 for use in a method for treating, preventing or slowing the progression of a disease requiring cholesteryl ester transfer protein inhibitor therapy. 
Spoj prema bilo kojem od zahtjeva 1 do 6 za uporabu u postupku liječenja, prevencije ili usporavanja napredovanja bolesti kod koje je potrebna terapija inhibitorom proteina prijenosnika kolesteril estera.
A compound of any one of claims 1 to 6 for use in a method of raising HDL cholesterol in a mammal. 
Spoj prema bilo kojem od zahtjeva 1 do 6 za uporabu u postupku povećanja HDL kolesterola kod sisavca.
Use of an IL-18BP isoform that lacks the ability to bind or neutralize IL-18 and that induces STAT2 nuclear translocation for the manufacture of a medicament for the treatment and/or the prevention of a neurological inflammatory disease, wherein said IL-18BP isoform is characterized by an amino acid sequence containing the 36 carboxy-terminal amino-acid of IL-18BPb (SEQ ID No. 
Uporaba IL-18BP izoforme kojoj nedostaje mogućnost vezanja ili neutralizacije IL-18 i koja izaziva STAT2 translokaciju jezgre za proizvodnju lijeka za liječenje i/ili prevenciju neurološke upalne bolesti, pri čemu je navedena IL-18BP izoforma naznačena time da aminokiselinska sekvenca sadrži 36 karboksi-završnih aminokiselina od IL-18BPb (SEQ ID No.
2) and is selected from the group consisting of 
2) te je odabrana iz skupine koja sadrži
a mutein of any of (a) to (e) which is encoded by a DNA sequence which hybridizes to the complement of the native DNA sequence encoding any of (a) to (e) under moderately stringent conditions or under highly stringent conditions; 
mutein bilo koje od (a) do (e) koji je kodiran sa DNA sekvencom koja hibridizira na komplement prirodne DNA sekvence koja enkodira bilo koju od (a) do (e) pod umjereno strogim uvjetima ili pod vrlo strogim uvjetima;
a mutein of any of (a) to (e) wherein any changes in the amino acid sequence are conservative amino acid substitutions to the amino acid sequences in (a) to (e); 
mutein bilo koje od (a) do (e) pri čemu bilo kakve promjene aminokiselinske sekvence su konzervativne zamjene amino kiseline sa aminokiselinskim sekvencama u (a) do (e);
The use according to claim 1, wherein the neurological and/or inflammatory disease is selected from the group consisting of traumatic nerve injury, stroke, demyelinating diseases of the CNS or PNS, neuropathies and chronic neurodegenerative diseases. 
Uporaba prema zahtjevu 1, naznačena time da neurološka i/ili upalna bolest je odabrana iz skupine koja sadrži traumatsku ozljedu živaca, srčani udar, demijelinizacijske bolesti CNS ili PNS, neuropatije i kronične neurodegenerativne bolesti.
The use according to claim 2, wherein the demyelinating diseases of the CNS or PNS is a peripheral neuropathy. 
Uporaba prema zahtjevu 2, naznačena time da demijelinizacijske bolesti CNS ili PNS su periferna neuropatija.
The use according to claim 1, wherein the neurological and/or inflammatory disease is caused by a congenital metabolic disorder. 
Uporaba prema zahtjevu 1, naznačena time da je neurološka i/ili upalna bolest uzrokovana sa nasljednim metaboličkim poremećajem.
The use according to any of claims 1 to 6, wherein said IL-18BP isoform is fused to a carrier molecule, a peptide or a protein that promotes the crossing of the blood brain barrier. 
Uporaba prema bilo kojem od zahtjeva 1 do 6, naznačena time da je navedena IL-18BP izoforma fuzionirana na molekulu nosač, na peptid ili na protein koja promiče prijelaz granice krv-mozak.
The use according to claim 7, wherein said IL-18BP isoform is fused to an immunoglobulin (Ig) domain. 
Uporaba prema zahtjevu 7, naznačena time navedena IL-18BP izoforma je spojena na imunoglobulinsku (Ig) domenu.
An IL-18BP isoform that lacks the ability to bind or neutralize IL-18 and that induces STAT2 nuclear translocation, wherein said IL-18BP isoform is characterized by an amino acid sequence containing the 36 carboxy-terminal amino-acid of IL-18BPb (SEQ ID No. 
IL-18BP izoforma kojoj nedostaje mogućnost vezanja ili neutralizacije IL-18 i koja izaziva STAT2 translokaciju jezgre, pri čemu je navedena IL-18BP izoforma naznačena time da aminokiselinska sekvenca sadrži 36 karboksi-završnih aminokiselina od IL-18BPb (SEQ ID No.
a mutein of any of (a) to (e) which is encoded by DNA sequence which hybridizes to the complement of the native DNA sequence encoding any of (a) to (e) under moderately stringent conditions or under highly stringent conditions; 
mutein bilo koje od (a) do (e) koji je kodiran sa DNA sekvencom koja hibridizira na komplement prirodne DNA sekvence koja kodira bilo koju od (a) do (e) pod umjereno strogim uvjetima ili pod vrlo strogim uvjetima;
a salt or a fused protein, functional derivative, active fraction or circularly permutated derivative of any of (a) to (h), the muteins, salts, fused proteins, functional derivatives, active fractions or circularly permutated derivatives of f) to i), retaining a similar, or even better, biological activity than the naturally occurring isoform for use in the treatment and/or the prevention of a neurological inflammatory disease. 
sol ili fuzionirani protein, funkcionalni derivat, aktivna frakcija ili kružno permutirani derivat bilo koje od (a) do (h), muteini, soli, fuzionirani proteini, funkcionalni derivati, aktivne frakcije ili kružno permutirani derivati od f) do i) koji zadržavaju sličnu ili čak bolju, biološku aktivnost nego oblik koji se javlja prirodno za uporabu kod liječenja i/ili prevencije neurološke upalne bolesti.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fenpropimorf.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
Process according to any of claims 1 to 7, characterised in that the di and/or trivalent cation salt(s) of one or more C8 to C24 aliphatic carboxylic acid(s) are di and/or trivalent cation salt of one or more C10 to C18, and preferably are di and/or trivalent cation salt of one or more C12 to C18 aliphatic carboxylic acid(s). 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time da dvovalentna i/ili trovalentna sol kationa jedne ili više C8 do C24 alifatske karboksilne kiseline odnosno alifatskih karboksilnih kiselina su dvovalentna i/ili trovalentna sol kationa jedne ili više C10 do C18 alifatskih karboksilnih kiselina, a poželjno su dvovalentna i/ili trovalentna sol kationa jedne ili više C12 do C18 alifatske karboksilne kiseline odnosno alifatskih karboksilnih kiselina.
Process according to any of claims 1 to 16, characterised in that the aliphatic carboxylic acid(s) provided to step (b) are in a molten state. 
Postupak prema bilo kojem od zahtjeva 1 do 16, naznačen time da se alifatska karboksilna kiselina (alifatske karboksilne kiseline) pripremljena u koraku (b) nalazi u rastaljenom stanju.
Use of a product obtained by a process according to any of claims 1 to 19 in a process of mixing and/or extruding and/or compounding and/or blow moulding with plastic materials. 
Uporaba produkta dobivenog pomoću postupka prema bilo kojem od zahtjeva 1 do 19 naznačena time da je za postupak miješanja i/ili ekstruzije i/ili kombiniranja i/ili injekcijskog prešanja plastičnih materijala.